Temozolomide for the Treatment of Recurrent Supratentorial Glioma: Results of a Compassionate use Program in Belgium

[1]  Susan M. Chang,et al.  Temozolomide in the treatment of recurrent malignant glioma , 2004, Cancer.

[2]  S. Ashley,et al.  Temozolomide as Second-line Chemotherapy for Relapsed Gliomas , 2002, Journal of Neuro-Oncology.

[3]  A. Cianciulli,et al.  Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  S. Ashley,et al.  Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  G. Sarris,et al.  311 Temozolomide (TMZ) combined with radiotherapy (RT) versus radiotherapy (RT) alone in newly diagnosed glioblastoma multiforme (GBM): A randomized phase III study , 2003 .

[6]  M. J. van den Bent,et al.  Recent developments in the molecular characterization and treatment of oligodendroglial tumors. , 2003, Neuro-oncology.

[7]  Allan H Friedman,et al.  Phase II trial of temozolomide in patients with progressive low-grade glioma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  A. Messori,et al.  Survival of Patients with Recurrent Malignant Glioma Treated with Temozolomide , 2003, Drugs in R&D.

[9]  J. Olson,et al.  A phase II study of temozolomide in patients with newly diagnosed supratentorial malignant glioma before radiation therapy. , 2002, Neuro-oncology.

[10]  L. Stewart,et al.  Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials , 2002, The Lancet.

[11]  Reto Meuli,et al.  Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  A. Brandes,et al.  Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: a phase II study. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  M Brada,et al.  Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  M. member.  Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a medical research council trial. , 2001 .

[15]  David M. Thomas,et al.  Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  L. Deangelis,et al.  Brain Tumors , 2019, Imaging Gliomas After Treatment.

[17]  D. Osoba,et al.  A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse , 2000, British Journal of Cancer.

[18]  D. Osoba,et al.  Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  G. Aravantinos,et al.  Phase II study of temozolomide in patients with relapsing high grade glioma and poor performance status , 2000, Medical oncology.

[20]  P. Beale,et al.  Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies , 1999, British Journal of Cancer.

[21]  Susan M. Chang,et al.  Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  J. Bruner,et al.  Descriptive epidemiology of primary brain and CNS tumors: results from the Central Brain Tumor Registry of the United States, 1990-1994. , 1999, Neuro-oncology.

[23]  R. Soffietti,et al.  PCV chemotherapy for recurrent oligodendrogliomas and oligoastrocytomas. , 1998, Neurosurgery.

[24]  A. Twijnstra,et al.  Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy , 1998, Neurology.

[25]  N. Bleehen,et al.  Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma , 1997, Cancer Chemotherapy and Pharmacology.

[26]  E. Newlands,et al.  The Charing Cross Hospital experience with temozolomide in patients with gliomas. , 1996, European journal of cancer.

[27]  E. Newlands,et al.  Potentiation of temozolomide and BCNU cytotoxicity by O(6)-benzylguanine: a comparative study in vitro. , 1996, British Journal of Cancer.

[28]  T. Cascino,et al.  Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  T. Cascino,et al.  Response criteria for phase II studies of supratentorial malignant glioma. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  R Simon,et al.  A non-parametric graphical representation of the relationship between survival and the occurrence of an event: application to responder versus non-responder bias. , 1984, Statistics in medicine.